March 22 WILKES-BARRE Following a meeting Tuesday night with President Donald Trump and House Speaker Paul Ryan, U.S. Rep. "President Trump and Speaker Ryan agreed with me last night that this is wrong and must be fixed," Barletta said. As long as his bill will receive full consideration next month, Barletta said he will vote for the AHCA.
The AHCA, unveiled earlier in March, would tie tax credits to age rather than income as well as roll back federal funding for the Medicaid expansion starting in 2020 and move the entitlement program to a per capita cap, among other changes. It has come under fire from a wide range of groups, including Heritage Action and Club for Growth as well as
Catalent has a long history supporting clients globally, including in Asia, in the development and supply of new drugs and consumer health products, and in clinical trial supply across the region. The Asia-Pacific region is strategically important for Catalent with high market growth and increased customer demand, and the company has continued to i
The results of a 2- year clinical trial on the drug sold as Repatha by Amgen Phamaceuticals that costs more than US $14,000 a year were released at theAmerican College of Cardiology annual conference in the US capital. "The drug was safe and well-tolerated," said lead study author Marc Sabatine, chair of cardiovascular medicine at Brigham and Wome
March 22 Determined to deliver an anniversary death blow to Barack Obama's signature health care law with a Thursday vote, congressional Republicans have been scrambling to get a holy mess of a replacement through the House. If their original "replacement" for the Affordable Care Act was flawed to the point of cruelty yanking health insurance f
The increasing prevalence of hospital acquired infections and the tremendous rise in geriatric populations are the major factors anticipated to encourage the growth of the global medical nonwoven disposables market.Albany, NY 03/22/2017 Global Medical Nonwoven Disposables Market: Overview. The global market for medical nonwoven disposables is
Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, today announced the pricing of its underwritten public offering of 4,500,000 shares of common stock at a price of $28.25 per share.
March 22 None of the approximately 18 patients who received dissolving stents at UPMC and Allegheny General Hospital reported the kind of major heart problems that the Food and Drug Administration warned about in a recent letter, according to the hospital systems. The FDA published a letter to cardiologists over the weekend warning the rate of he
An increasing number of surgical procedures, rising health and hygiene concerns, and product innovation are the major factors that have led to a rise in demand for surgical and respirator masks, thereby driving the growth of the surgical and respirator masks market.New York, NY 03/22/2017 According to a new market report published by Persiste
TARRYTOWN, N.Y., March 22, 2017/ PRNewswire/ Regeneron Pharmaceuticals, Inc., today announced a major research initiative among the Regeneron Genetics Center, U.K. Biobank and GSK to generate genetic sequence data from the 500,000 volunteer participants in the U.K. Biobank resource. The initiative will enable researchers to gain valuable insights
Global PVC Market is expected to reach USD 78.90 billion in 2021, growing at a CAGR of 5.6% between 2016 and 2021 Sarasota, FL 03/21/2017 Zion Market Research has published a new report titled " PVC Market by Application For Automotive, Electrical& Electronics, Construction, Packaging And Other End-User: Global Industry Perspective, Comprehen
Moleculin Biotech Inc shares surged 28 percent to $1.37 after the company reported that its AML treatment liposomal annamycin has been awarded the FDA Orphan Drug designation. Innocoll Holdings PLC shares rose 22.9 percent to $1.29. Interpace Diagnostics Group Inc shares gained 16.3 percent to $2.85 on volume. Cleantech Solutions International Inc.
Gainers bebe stores, inc. rose 33.1 percent to $4.75 in pre-market trading after dropping 44.65 percent on Tuesday. Achillion Pharmaceuticals, Inc. rose 18.5 percent to $4.55 in pre-market trading after the company disclosed that the USPTO has granted composition of matter patent to company for small molecule complement alternative pathway factor D
This new report from VPGMarketResearch.com is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the molecular diagnostics market during the next five years. -Five-year test volume and sales forecasts- Feature comparison of major analyzers- Profiles of market players and start-up firms
When Virginia Republicans persistently resisted new Medicaid funds under the Affordable Health Care Act, we weren't entirely unsympathetic. Then, if Medicaid coverage were to be continued for all of the newly insured, the state would have been on the hook for the additional funding. Various estimates disagreed on how much that would be; that very l
Achillion Pharmaceuticals, Inc. dipped 0.5% to $3.82 after the company disclosed that the USPTO has granted composition of matter patent to company for small molecule complement alternative pathway factor D inhibitors.
Advanced ICU Care, the nation s leading provider of high-acuity telemedicine, announced the launch of tele-ICU services at Memorial Healthcare in Owosso, Michigan. With launch of tele-ICU care at Memorial Healthcare, the Advanced ICU Care team of board certified intensivists and highly trained critical care nurses provide round-the-clock monitor
Aegis Medical Innovations Inc. today announced that it has received Investigational Device Exemption approval from the U.S. FDA to initiate a clinical trial in the U.S. for its medical device called the Sierra Ligation System. Aegis developed the Sierra technology in partnership with the Mayo Clinic in Rochester, MN. Sierra could, with additional c
Despite false rhetoric that current law burdens American households with high out-of-pocket costs, the replacement plan put forth by President Trump and Republicans in Congress, known as the American Health Care Act, would substantially increase out-of-pocket costs. According to a new analysis by EPI Research Director Josh Bivens, Americans would p
Akashi Therapeutics, Inc. a clinical stage biopharmaceutical company developing treatments for patients with Duchenne muscular dystrophy, today reported that the U.S. Food and Drug Administration has completed its review and concluded that Akashi may resume clinical development of HT-100 in patients with any of the genetic mutations that cause DMD,
Allergan plc today announced the availability of RESTASIS MULTIDOSE?, which is the same preservative-free RESTASIS formulation, but now offered in a multidose bottle. RESTASIS MultiDose? is the first and only FDA- approved preservative-free, prescription eye drop in the U.S. to be available in a multidose bottle. "Since RESTASIS MultiDose
The Alliance is pleased that the Senate Health, Education, Labor, and Pensions Committee and the House Energy and Commerce Committee held their first hearings on the reauthorization of the FDA's prescription drug and medical device user fee programs. The Alliance has worked with the FDA for more than a decade to streamline the clinical development
"Competing with more than 80 contract manufacturers, AMRI is honored to be recognized by our customers from industry pharma and biopharma companies," said William S. Marth, president and CEO, AMRI. The CMO Leadership Awards are presented annually by Life Science Leader, with winners chosen based on research conducted by Industry Standard Research.
The American Psychiatric Association issued the following statement by President Maria A. Oquendo on the House to reject American Health Care Act:. "The AHCA will remove insurance coverage from millions of Americans who will not be able to access treatment otherwise. Unfortunately, we cannot support the AHCA bill because it is not a solution. "
BOSTON and STOCKHOLM, March 22, 2017/ PRNewswire/ Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, today announced a collaboration with Memorial Sloan Kettering Cancer Center to study the effects of reactivation of tumor suppressor prot